Product Information
BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.2207 per EA under NDC 70954041440. Its NADAC has been published 145 times since Nov 16, 2022.
FDA first approved this application on Nov 4, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Bisoprolol Fumarate and Hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB
Bisoprolol Fumarate and HydrochlorothiazideStrength
10; 6.25 mg/1; mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
70954041440
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
8/20/2025
Active Ingredients
BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215562FDA Approved
11/4/2021
TE Code
AB
On Market Since
11/4/2021
Pharmacological Classes
Price Statistics
The NADAC for BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB has been published 145 times since Nov 16, 2022, and over the history we have for it it has declined 36.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2207 per EA |
|---|---|
| All-time high | $0.3489 (Nov 16, 2022) |
| All-time low | $0.1227 (Nov 20, 2024) |
| Median price | $0.2460 |
| Average price | $0.2432 |
| Largest weekly change | +49.9% (Dec 18, 2024) |
| Weeks tracked | 145 |
| Tracking since | Nov 16, 2022 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-17.3%
5Y
N/A
All
-36.7%
Last surveyed Aug 20, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB, manufactured by ANI Pharmaceuticals, Inc., is $0.2207 per EA (NDC 70954041440), effective Aug 20, 2025.
How has the price of BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB changed over time?
Over the history we have for it, the NADAC for BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB has declined 36.7%. It has been tracked across 145 weekly CMS publications since Nov 16, 2022.
What are the highest and lowest recorded NADAC prices for BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB?
Since Nov 16, 2022, the NADAC for BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB has ranged from a low of $0.1227 (Nov 20, 2024) to a high of $0.3489 (Nov 16, 2022), with a median of $0.2460 per EA.
Are there cheaper alternatives to BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB, is $0.2096 per EA — about 5% below BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB.
Who manufactures BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB?
BISOPROLOL-HYDROCHLOROTHIAZIDE 10-6.25 MG TAB (NDC 70954041440) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.